SLC10A2 and metabolic dysfunction-associated steatohepatitis: Volixibat (SHP626; formerly LUM002) is a highly potent, minimally absorbed, competitive inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that is being developed as a potential pharmacological treatment for NASH [21].